ergosta‑7,22‑dienol

Ergosta‑7,22‑dienol is a sterol‑class organic compound predominantly identified in fungi and certain mushroom species. Chemically, it belongs to a family of ergostane sterols, with a structure characterized by a 28‑carbon backbone and unsaturated bonds at the 7 and 22 positions, and a hydroxyl moiety at the 3β position. These fungal sterols play roles analogous to cholesterol in animals, contributing to membrane structure and fluidity. In biochemical contexts, ergosta‑7,22‑dienol is detected as a minor component of sterol profiles and is sometimes referred to by synonyms such as ergostadienol or ergostane‑7,22‑dien‑3β‑ol. Data from chemical databases describe its molecular formula as C28H46O with a relatively high boiling point and non‑volatile properties, reflecting its sterol nature. However, unlike essential vitamins or minerals, ergosta‑7,22‑dienol has not been recognized by major nutritional authorities (such as NIH or USDA) as an essential human nutrient with established dietary requirements (as indicated by a lack of NIH fact sheets or dietary reference values). Its biological relevance to humans is inferred mainly from its role in fungal physiology and limited laboratory research rather than from robust human nutritional studies. Within fungi, sterol compounds such as ergosta‑7,22‑dienol may influence membrane dynamics and act as precursors to other biologically active sterols. Despite this, mainstream clinical nutrition does not classify ergosta‑7,22‑dienol as a required nutrient for human health. Instead, most research has focused on related ergosterol compounds and their derivatives, which in some contexts serve as precursors to vitamin D analogues when exposed to ultraviolet light. Currently, ergosta‑7,22‑dienol remains primarily of interest in biochemical and pharmacological research rather than as a defined dietary component.

Because ergosta‑7,22‑dienol is not an established human nutrient, its putative functions or health benefits for humans are not defined by authoritative health bodies. Research into ergosta‑7,22‑dienol and structurally related sterols has largely occurred in laboratory and preclinical settings rather than in human clinical trials. In fungal biology, sterols such as ergosta‑7,22‑dienol and its analogues contribute to cell membrane structure, influencing membrane permeability and fluidity. These biochemical roles are essential for fungal survival but do not directly translate into defined nutritional functions in humans. Some related compounds, such as ergosta‑7,22‑diene‑2β,3α,9α‑triol (a derivative isolated from Ganoderma lucidum), have been investigated for potential bioactivities, including apoptotic effects on cancer cell lines in vitro. For example, one laboratory study reported that this derivative induced apoptosis in human leukemia cells by activating caspase pathways and promoting DNA fragmentation, suggesting potential antitumor mechanisms in controlled settings. Additional preclinical research has indicated that such compounds might influence signaling pathways, including blockade of epidermal growth factor receptor (EGFR) and downstream signaling, showing inhibition of tumor growth in xenograft models. These findings, while intriguing, remain preliminary and are not evidence of health benefits from dietary consumption in humans. Importantly, there are no large‑scale randomized controlled trials or systematic reviews available that link dietary intake of ergosta‑7,22‑dienol with specific health outcomes. Without such evidence, authoritative guidance cannot recommend ergosta‑7,22‑dienol for disease prevention, metabolic support, or other health benefits. In contrast, well‑studied sterol compounds (such as plant sterols) have defined roles in cholesterol metabolism, but ergosta‑7,22‑dienol does not belong to that category of clinically validated nutrients. Therefore, any discussion of health benefits should be framed within the context of ongoing research rather than established nutritional science. Current evidence is insufficient to support claims that ergosta‑7,22‑dienol confers measurable health benefits when consumed as part of the diet.

Unlike essential vitamins or minerals, ergosta‑7,22‑dienol does not have established dietary reference intakes (DRIs) such as a recommended dietary allowance (RDA), adequate intake (AI), or tolerable upper intake level (UL). Major health authorities, including the National Institutes of Health and the USDA, do not recognize ergosta‑7,22‑dienol as an essential nutrient for human health; thus no age‑ or sex‑specific intake values have been set. In the absence of official guidelines, no specific quantity can be defined as a nutritional requirement. Instead, ergosta‑7,22‑dienol intake occurs incidentally through consumption of foods that contain trace amounts of this sterol, particularly certain mushrooms. One food composition database suggests that champignon mushrooms contain approximately 5.9 mg of ergosta‑7,22‑dienol per 100 g serving, with other common foods reporting negligible amounts. Whether this intake has any physiological impact is currently unknown. Without established needs, it is also not possible to define optimal vs minimal intake levels, or to assess sufficiency. In contrast, essential sterols such as cholesterol have well‑defined physiological requirements because of their roles in cell membrane integrity and hormone synthesis. Conversely, ergosta‑7,22‑dienol’s role in human metabolism is not established, and it is not involved in key pathways recognized as necessary for human survival or health. Therefore, individuals do not need to seek out ergosta‑7,22‑dienol for health purposes, and its presence in foods should be considered incidental. The concept of dietary needs for non‑nutrient compounds is more relevant in the context of bioactive food components, where research may explore potential health effects without establishing nutritional requirements. In that sense, ergosta‑7,22‑dienol may be studied for possible biological effects, but current evidence does not support intake recommendations.

Because ergosta‑7,22‑dienol is not recognized as an essential nutrient in human physiology, there are no defined clinical deficiency signs or symptoms. Established deficiency syndromes exist for nutrients like vitamin C (scurvy) or vitamin D (rickets/osteomalacia), where specific biochemical pathways and physiological functions are disrupted by inadequate intake. Ergosta‑7,22‑dienol, in contrast, has no known role in essential human metabolic processes; therefore, its absence does not produce a recognized deficiency disease. Reports from scientific literature focus on the compound’s presence in fungal organisms and occasionally on its derivative bioactivities in laboratory models. For instance, certain ergosta derivatives have demonstrated apoptosis induction in cultured cancer cells or blockage of growth factor signaling pathways in xenograft models, but such findings relate to pharmacological potential rather than nutritional status. No data exist indicating that humans experience physiological impairment attributable to low levels of ergosta‑7,22‑dienol, nor are there clinical tests that measure its concentration in human tissues or blood. Without a functional requirement or established homeostatic mechanisms, deficiency metrics such as prevalence in specific populations or severity gradations do not apply. As a result, at‑risk populations for deficiency cannot be identified. Because ergosta‑7,22‑dienol is not required for health, there is no diagnostic criteria for insufficiency or deficiency. Researchers interested in fungal sterols investigate their roles in fungal cell biology or as leads for pharmacological agents rather than as human nutrients. Consequently, this section serves to clarify that ergosta‑7,22‑dienol deficiency is not a medically recognized condition and thus lacks clinical signs, laboratory reference ranges, or prevalence statistics.

Ergosta‑7,22‑dienol occurs at low levels in certain foods, primarily fungi and mushroom species. Food composition databases that include sterol profiling indicate that champignon mushrooms (Agaricus bisporus) contain ergosta‑7,22‑dienol at approximately 5.9 mg per 100 g serving. Other foods, including meats, legumes, vegetables, and dairy products, typically report negligible or undetectable amounts of ergosta‑7,22‑dienol. This limited distribution reflects the compound’s biosynthesis in fungal organisms rather than in plants or animals. Industrially cultivated mushrooms and wild edible fungi may vary in sterol content, with some medicinal mushrooms such as Ganoderma species (reishi) containing related sterol derivatives. However, comprehensive food databases with quantified values for ergosta‑7,22‑dienol across a wide range of foods are scarce, and most values beyond champignon mushrooms are either zero or not reported. When considering food sources, it is important to recognize that sterol profiles can differ based on factors such as species, growing conditions, maturity at harvest, and post‑harvest handling. In the case of champignon mushrooms, the approximately 5.9 mg per 100 g value provides a rare quantified instance of ergosta‑7,22‑dienol content, but it does not imply a health requirement. The following table lists foods with available data, noting that many report zero content for ergosta‑7,22‑dienol. In culinary practice, mushrooms provide a variety of phytochemicals and nutrients, even if ergosta‑7,22‑dienol itself is not a target nutrient. Therefore, while the presence of ergosta‑7,22‑dienol can be reported, dietary choices should be guided by established nutrient content rather than trace sterol levels.

Because ergosta‑7,22‑dienol is not an established dietary nutrient with known physiological roles in humans, there is minimal research on its absorption, metabolism, or bioavailability in humans. Sterol compounds in general, such as cholesterol or plant sterols (phytosterols), follow defined absorption pathways in the human gut, often involving incorporation into micelles and uptake mediated by specific transporters. However, the human digestive system is adapted mainly to absorb cholesterol and other common dietary lipids rather than minor fungal sterols like ergosta‑7,22‑dienol. Should ergosta‑7,22‑dienol be consumed through foods such as mushrooms, it would likely behave similarly to other non‑cholesterol sterols, with low absorption efficiency due to poor solubility and limited affinity for intestinal transport mechanisms. Studies of plant sterols have shown that factors such as dietary fat content, bile acid secretion, and food matrix influence sterol absorption. By analogy, if ergosta‑7,22‑dienol were to be absorbed, its uptake might be enhanced in the presence of dietary fats that stimulate bile acid release, promoting micelle formation. Conversely, components like phytates, fibers, and certain plant proteins could inhibit absorption by binding sterols or altering micellar dynamics. Nonetheless, without direct research, these analogies remain speculative. Furthermore, there is no evidence that humans convert ergosta‑7,22‑dienol into other metabolites of nutritional significance. In contrast to ergosterol, which can be converted to vitamin D2 upon ultraviolet light exposure, ergosta‑7,22‑dienol does not serve as a recognized precursor for essential vitamins. Overall, the lack of data on absorption and metabolism underscores the limited nutritional relevance of ergosta‑7,22‑dienol in human diets.

Given the absence of evidence that ergosta‑7,22‑dienol is required for human health, supplements containing this compound are not recommended for general nutritional purposes. Unlike vitamins, minerals, and essential fatty acids, which have well‑defined roles and intake recommendations, ergosta‑7,22‑dienol lacks data demonstrating benefits from supplementation in humans. Commercial supplements marketed for health often include sterol derivatives such as plant sterols for cholesterol management, but ergosta‑7,22‑dienol specifically is not included in mainstream supplement formulations backed by clinical evidence. Laboratory studies on related compounds isolated from mushrooms (e.g., derivatives with potential apoptotic effects on cancer cells) are preliminary and do not justify human supplementation. Importantly, supplements containing ergosta‑7,22‑dienol or its analogues are not regulated as essential nutrients, and their safety and efficacy have not been established. If individuals encounter products claiming benefits from ergosta‑7,22‑dienol, they should approach with caution and consult healthcare professionals. For most people, focusing on a diet rich in well‑studied nutrients and food bioactives—such as vitamins, minerals, fiber, and antioxidants from fruits, vegetables, lean proteins, and whole grains—remains the foundation of nutritional health. Supplements may be appropriate when nutrient deficiencies are identified or when specific health conditions warrant targeted intake, but ergosta‑7,22‑dienol does not meet these criteria. Therefore, there is no recommended dosage, form, or timing for ergosta‑7,22‑dienol supplementation.

There are no established toxicological profiles or tolerable upper intake levels (ULs) for ergosta‑7,22‑dienol because it is not an essential human nutrient and has not been the subject of safety evaluations by major health authorities. Available chemical database entries describe physical properties of ergosta‑7,22‑dienol but do not provide evidence of toxicity in humans. Some structurally related sterol compounds found in yeast, such as cerevisterol, have demonstrated cytotoxicity in vitro to certain mammalian cell lines, but these findings pertain to isolated cellular models rather than dietary exposure. Without human clinical data, it is not possible to define symptoms of excess intake, risk factors for overconsumption, or specific upper limits. Intake through normal dietary sources, such as mushrooms, is expected to be very low, and there are no reports of adverse effects attributable to ergosta‑7,22‑dienol from food. Nonetheless, because supplements containing isolated sterols are not regulated for efficacy or safety, individuals should exercise caution with any product claiming health effects from ergosta‑7,22‑dienol or related compounds, particularly at high doses. Consultation with healthcare professionals is advisable before using such products, especially for those with underlying health conditions.

There is no clinical evidence regarding drug interactions specific to ergosta‑7,22‑dienol. Unlike established nutrients such as vitamin K (which can interact with anticoagulant medications) or magnesium (which can affect certain antibiotics), ergosta‑7,22‑dienol has not been studied in pharmacokinetic or pharmacodynamic contexts in humans. Without data on absorption, metabolism, or biological activity in humans, it is not possible to delineate interactions with medications. If ergosta‑7,22‑dienol or related sterol derivatives were used experimentally in laboratory or pharmacological research, any reported effects on cell signaling or enzyme pathways would be context‑specific and not directly applicable to typical human drug use. Therefore, individuals taking prescription medications should not expect ergosta‑7,22‑dienol consumption to influence drug efficacy or safety, and no adjustments to medication regimens are recommended on this basis. As with any compound not recognized as a nutrient, caution and professional medical guidance are advised when considering consumption in conjunction with medication.